Our results concur with Vizcarra et al., a dopamine transporter deficiency measured with SPECT, predicts a much better response to levodopa therapy, and therefore dopamine transporter deficiency can be a good predictor of levodopa response in VP patients. This evidence concerns the gene SLC6A3 and hyperinsulinemic hypoglycemia, familial, 4.